A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00879086
- Locations
- ๐บ๐ธ
Northwest Cancer Center, Corpus Christi, Texas, United States
๐บ๐ธTexas Oncology-Sammons Cancer Center, Dallas, Texas, United States
๐บ๐ธNorthern Utah Associates, Ogden, Utah, United States
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00869895
- Locations
- ๐ฌ๐ง
Christie Hospital, Manchester, United Kingdom
๐ฌ๐งRoyal Marsden Hospital, Surrey, United Kingdom
Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 295
- Registration Number
- NCT00848549
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
- Conditions
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00839306
- Locations
- ๐บ๐ธ
Midwest Clinical, Moline, Illinois, United States
๐บ๐ธAssociates, Ltd., Moline, Illinois, United States
๐บ๐ธResearch, Moline, Illinois, United States
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
- Conditions
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00838526
- Locations
- ๐บ๐ธ
Ltd., Moline, Illinois, United States
๐บ๐ธResearch Associates, Moline, Illinois, United States
๐บ๐ธMidwest Clinical, Moline, Illinois, United States
Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00828438
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00828581
- Locations
- ๐บ๐ธ
CRI Worldwide - Lourdes Hospital, Willingboro, New Jersey, United States
Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT00828659
- Locations
- ๐จ๐ฆ
Kendle Early Phase, Toronto, Toronto, Ontario, Canada
To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00829140
- Locations
- ๐บ๐ธ
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00828724
- Locations
- ๐บ๐ธ
CRI Worldwide, Willingboro, New Jersey, United States